RxDoctor Payments Data

Robert Elliott, DO

Internal Medicine · Rancho Mirage, CANPI 1699270355

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 41 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$284
  • Novo Nordisk$227
  • Viiv Healthcare Company$225
  • Inari Medical, Inc.$183
  • GSK$94
  • Lilly USA, LLC$58
  • plus $155 from 5 others

What the payments were for

  • Food & beverage$1,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,226 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$44,240
Medicare patients
94
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$18,186
Lidocaine13$873
Bupropion XlBupropion Hcl15$790
Losartan Potassium40$596
Gabapentin30$525
ValacyclovirValacyclovir Hcl15$486
Atorvastatin Calcium47$469
Fluticasone Propionate23$432
Levothyroxine Sodium24$333
Rosuvastatin Calcium29$246
Tamsulosin Hcl13$220
Metformin Hcl19$156
Omeprazole14$152
Trazodone Hcl15$149
Amlodipine Besylate25$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$227$18,18620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →